Scientists are expected to develop new vaccines against early breast cancer January 05, 2017 Source: Bio Valley Abnormal regulation and inhibition of the immune system often induce cancer, and many therapeutic strategies aim to reactivate the body's immune system to recognize cancer cells and target cancer cells; a recent publication in the international journal Clinical Cancer Research In a research report, researchers from the Mofate Cancer Research Center have developed a dendritic cell vaccine that targets HER2 proteins on the surface of breast cancer cells. This new vaccine can safely and effectively stimulate the body's immune response. Effectively reverse the occurrence of early breast cancer. HER2 protein is overexpressed in approximately 20% to 25% of breast cancer tumors, and this protein is directly related to the malignancy of breast cancer and the poor prognosis of patients. Previous studies by researchers have shown that immune cells are not effectively recognized. And targeting cancer cells that express HER2 protein, and HER2 can serve as a marker for the progression of cancer to a malignant invasive stage, suggesting that the strategy of stimulating the body's immune system to recognize and target HER2 during cancer development may be An effective therapeutic strategy. Previously, researchers have developed a vaccine that helps the body's immune system recognize HER2 proteins on the surface of breast cancer cells. This approach involves collecting dendritic cells from each patient's body and using these dendritic cells to create individualized vaccines. To determine the safety and efficacy of this HER2-dendritic cell vaccine, the researchers conducted a clinical trial of 54 women with early-stage breast cancer expressing HER2. First, the researchers isolated dendritic cells from the blood of each patient and Dendritic cells are exposed to fragments of the HER2 protein, which is well prepared for the development of dendritic cell vaccines, and the investigator then injects this individualized dendritic cell vaccine into the patient's lymph nodes, once a week. Continuous injection for 6 weeks. The researchers found that this dendritic cell vaccine is well tolerated, and patients only experience a lower degree of toxic effects. The most common side effects of patients are fatigue, injection site reaction, and chills; Effectively activates the immune response of the vast majority of patients, and then the researchers detected a certain immune response in the sentinel lymph nodes and peripheral blood of about 80% of the patients evaluated. More importantly, the immune responses generated in these patients' bodies There is a certain similarity, which is not related to the procedure and dosage of the patient to vaccinate. The researchers evaluated the efficacy of this novel dendritic cell vaccine by determining the proportion of patients who were able to detect the disease in the postoperative specimen. The absence of disease was considered to be a pathological complete response (pCR). It was found that 13 patients achieved pCR performance, and patients with early non-invasive ductal carcinoma of the intestine achieved a higher proportion of pCR status, more interesting than patients with early invasive cancer. Yes, a higher level of immune response is produced in local sentinel lymph nodes in the body of the patient who achieves pCR. The final researcher Brian J. Czerniecki said that the results of this study indicate that this new vaccine is effective in the treatment of ductal carcinoma in situ, but in the later stage we need further testing in ductal carcinoma in situ and other cancers. The sentinel lymph nodes of the region may serve as a more meaningful immune endpoint. Blood Pressure Transducer,blood pressure monitor,blood pressure machine,blood pressure monitor price,blood pressure Anesthesia Medical Co., Ltd. , https://www.medicaldiverse.com
Scientists are expected to develop new vaccines against early breast cancer